


image

\$



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Beechem *et al.*

Serial No.: 10/666,291

Filed: September 17, 2003

For: **Antibody Complexes and Methods
for Immunolabeling**

)
)
) Examiner: Not Yet Known
)
) Group Art Unit: Not Yet Known
) **TRANSMITTAL LETTER**
)
)

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith are the following documents in the above-identified application.

- [X] Supplemental Information Disclosure Statement
- [X] Substituted USPTO Form 1449
- [X] Cited References A53-A54 and C13-C24
- [X] Fee Transmittal Form (PTO/SB/17)
- [X] Return Postcard (Postage Prepaid)

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED TO AS BEING ATTACHED OR ENCLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON April 6, 2004 AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450 ALEXANDRIA, VA 22313-1450.

By me d. S., Michael A. Sennett

Beechem *et al.*
10/666,291

Respectfully submitted,

Date: April 6, 2004

Karen J. Anderson
Karen J. Anderson, Ph.D.
Reg. No. 51,061

Molecular Probes, Inc.
29851 Willow Creek
Eugene, Oregon, 97402
Phone: (541) 335-0203
Facsimile: (541) 335-0188



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

Complete if Known

Application Number	10/666,291
Filing Date	September 14, 2003
First Named Inventor	Joseph Beechem
Examiner Name	
Art Unit	
Attorney Docket No.	

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number 13-3900

Deposit Account Name Molecular Probes, Inc.

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$) 0.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims		Extra Claims		Fee from below		Fee Paid
Independent		-20** =		X		
Multiple Dependent		-3** =		X		

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1202	18	2202	9	Claims in excess of 20	
1201	86	2201	43	Independent claims in excess of 3	
1203	290	2203	145	Multiple dependent claim, if not paid	
1204	86	2204	43	** Reissue independent claims over original patent	
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent	

SUBTOTAL (2) (\$) 0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 180.00

SUBMITTED BY

(Complete if applicable)

Name (Print/Type)	Koren J. Anderson	Registration No. (Attorney/Agent)	51,061	Telephone	541-335-0203
Signature	<i>Koren J. Anderson</i>	Date	4/10/04		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Beechem *et al.*)
Serial No.: 10/666,291) Examiner: Not Yet Known
Filed: September 17, 2003) Group Art Unit: Not Yet Known
For: **Antibody Complexes and Methods**) **SUPPLEMENTAL INFORMATION**
for Immunolabeling) **DISCLOSURE STATEMENT**

Commissioner for Patents
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.97(c) The Supplemental Information Disclosure Statement (IDS) being transmitted herewith is being filed after the mailing date of the first Office Action on the merits but before the mailing date of an action that effectively closes prosecution on the merits. Accordingly, a fee specified in CFR 1.17(p) and the statement specified in paragraph (e) of 37 CFR 1.97 is hereby submitted with this IDS.

In accordance with 37 CFR 1.97(e)(2), Applicants hereby certify that no item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application and no item of information contained in the information disclosure statement was known more than three months prior to filing of this IDS.

Applicants, respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. The Examiner is requested to initial and return the enclosed PTO-1449 form in accordance with MPEP §609.

This Information Disclosure Statement pursuant to 37 CFR 1.97 is not to be construed as a representation that: (1) a search has been made; (2) the above information constitutes prior art to the subject invention. Accordingly, it is requested that the Examiner consider the enclosed references.

04/14/2004 BABRAHA1 00000136 133900 10666291
01 FC:1806 180.00 DA

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED TO AS BEING ATTACHED OR ENCLOSED HERewith ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON April 6, 2004 AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450 ALEXANDRIA, VA 22313-1450.

By Michael A. Sennett


Beechem *et al.*
10/666,291

Respectfully submitted,

Date: April 6, 2004

Koren J. Anderson
Koren J. Anderson, Ph.D.
Reg. No. 51,061

Molecular Probes, Inc.
29851 Willow Creek Road
Eugene, Oregon, 97402
Phone: (541) 335-0203
Facsimile: (541) 335-0188



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

Docket:

Ser: 10/666,291

Applicant: Beechem, et al.

Filed:

September 17, 2003

Group:

U.S. PATENT DOCUMENTS

Init.*	Cite No.	Number	Date	Name	Class	Sub	Filed
	A53	US 2002/0064794	05/30/02	Leung et al.			
	A54	US 2002/0077487	06/20/02	Leung et al.			

NON PATENT LITERATURE DOCUMENTS

Init.*	Cite No.	Name of Author, Title of the Article, Title of the Item, Date, Page, Volume-Issue Number
	C13	✓ Matayoshi, E. D., G. T. Wang, et al. (1990). "Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer." <i>Science</i> 247 (4945): 954-8.
	C14	✓ dos Remedios, C. G. and P. D. Moens (1995). "Fluorescence resonance energy transfer spectroscopy is a reliable "ruler" for measuring structural changes in proteins. Dispelling the problem of the unknown orientation factor." <i>J Struct Biol</i> 115 (2): 175-85.
	C15	✓ Selvin, P. R. (1995). "Fluorescence resonance energy transfer." <i>Methods Enzymol</i> 246 : 300-34.
	C16	✓ Zhang, K., D. Baeckstrom, et al. (1994). "A secreted mucin carrying sialyl-Lewis a from colon carcinoma cells binds to E-selectin and inhibits HL-60 cell adhesion." <i>Int J Cancer</i> 59 (6): 823-9.
	C17	✓ Capo, C., Z. Mishal, et al. (1983). "Dimethylsulphoxide induction of the murine macrophage-like line P388D1: change of phagocytic ability and cell surface properties." <i>J Cell Sci</i> 64 : 281-93.
	C18	✓ Davidson-Moncada, J. K., G. Lopez-Lluch, et al. (2002). "Involvement of protein kinase D in Fc gamma-receptor activation of the NADPH oxidase in neutrophils." <i>Biochem J</i> 363 (Pt 1): 95-103.
	C19	✓ Kimura, S., M. Numaguchi, et al. (2000). "High galactosylation of oligosaccharides in umbilical cord blood IgG, and its relationship to placental function." <i>Clin Chim Acta</i> 299 (1-2): 169-77.
	C20	✓ Marshall, L. R., F. E. Brogden, et al. (1994). "Antenatal platelet antibody testing by flow cytometry--results of a pilot study." <i>Transfusion</i> 34 (11): 961-5.
	C21	✓ Friedman, M. G. (1981). "A population screening test for antibody to measles virus." <i>Isr J Med Sci</i> 17 (11): 1045-50.
	C22	✓ Zhang, J. H., T. D. Chung, et al. (1999). "A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays." <i>J Biomol Screen</i> 4 (2): 67-73.
	C23	✓ Kricka, L. J. (1992). <i>Nonisotopic DNA Probe Techniques</i> . San Diego: Academic Press, Inc.
	C24	✓ <i>Decision on Appeal: Hearing Before the Board of Patent Appeals and Interferences, United States Patent and Trademark Office, Appeal No. 95-4481, Application 07/911,667.</i>

EXAMINER:

DATE:

*Examiner: Initial if considered, whether or not in conformance with MPEP 60; draw line through cite if not in conformance and not considered. Send copy.